DOT1L inhibitor EPZ5676 was trialled in pediatric and adult patients with KMT2Ar refractory or relapsed leukemia (NCT02141828 and NCT01684150 clinical trials) (Yi and Ge, 2022). Here, DOT1L is linked to leukemia.